RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Jun 7, 2013 - 3:10:59 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Second annual Brain Tumor Biotech Summit 2013 at Weill Cornell

Jun 7, 2013 - 4:00:00 AM
The Summit also represents a new way to engage academia, industry and investors in collaborative research. Not only are experts at Weill Cornell adopting the approach for other key areas of neurosurgery, including concussion, spinal cord injury and stroke, but other institutions are also replicating the format to spur research within their own facilities.

 
[RxPG] NEW YORK (June 7, 2013) -- The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bidto accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.

Regardless of our backgrounds, our shared vision and purpose today was to bridge the gap between basic and clinical science, says Dr. John Boockvar, chair of the Summit, director of the Brain Tumor Research Group, professor of neurological surgery at Weill Cornell Medical College and a neurosurgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. It often takes decades to realize discoveries from bench to bedside when it needs to be a few years. This dynamic meeting advanced collaborations vital to accelerating the translation of new scientific findings into novel therapeutics that can be delivered rapidly to our patients.

More than 23,000 people in the United States will be diagnosed with brain or spinal tumors this year and more than 14,000 patients will succumb to their disease, according to the American Cancer Society. With the patient median survival rate of 15 months, there is a crucial need to identify more effective treatments for brain tumors that will not only extend life, but also lead to potential cures.

Brain cancer touches the lives of thousands of families a year, and it is incumbent upon us to devise novel treatments and therapeutics that will better target malignant tumors and enhance human health, adds Dr. Lewis Cantley, the Margaret and Herman Sokol Professor in Oncology Research and professor of cancer biology in medicine at Weill Cornell and director of the Cancer Center at Weill Cornell and NewYork-Presbyterian Hospital. However, as federal funding for research has plummeted -- hastened under sequestration -- it is become more important than ever for brain tumor researchers to supplement their government grants with private funding to advance their research.

Industry leaders from the biotech industry, venture capital firms, finance, non-profit foundations and pharmaceutical companies participated in the Brain Tumor Biotech Summit discussions regarding ways to get new research findings noticed and funded. Top brain tumor researchers from across the country presented their latest advances in vaccine treatments, nanotechnology, stem cell biology, angiogenesis, gene therapy, targeted therapeutics, novel medical devices and a host of other topics relevant to the diagnosis and treatment of human cancer.

The Brain Tumor Biotech Summit is the only place that interfaces scientists, clinicians, financial investors and the biotech industry. I know of no other place that brings those four groups together, says Franklin Berger, a leading biotech industry expert and moderator of the VC Roundtable: How to Get Your Research or Company Noticed? Lessons from the Investment Experts panel discussion at the Summit. That's critical because the cost and time required to get a therapy across the finish line, from thought to vial, is longer and more complex than ever.

The Summit also represents a new way to engage academia, industry and investors in collaborative research. Not only are experts at Weill Cornell adopting the approach for other key areas of neurosurgery, including concussion, spinal cord injury and stroke, but other institutions are also replicating the format to spur research within their own facilities.

The Summit is an amalgamation of thought leaders in the areas of science, industry and venture capital who collectively have already expanded the boundaries in brain tumor research, leading to novel ideas and new clinical trials. This year's Summit forged new, game-changing relationships, and I'm excited to see the advancements in brain tumor treatments that will be catalyzed as a result, says Dr. Philip E. Stieg, professor and chairman of neurological surgery at Weill Cornell Medical College and neurosurgeon-in-chief at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.



Related Latest Research News
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Book explores undiscovered economics of everyday life
Gene and stem cell therapy combination could aid wound healing
Solving the internet capacity crunch
Breathing new life into preterm baby research
Perceptions of the role of the state shape water services provision

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)